

ASX RELEASE

19 December 2024

Results of Extraordinary General Meeting

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to confirm that each of the resolutions put to its Extraordinary General Meeting held earlier today were **carried**.

Details of the results of the meeting are attached.

This ASX announcement is authorised for release by the Company Secretary.

- End -

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](#) (@ampliatx), [Threads](#) (@ampliatx) and [LinkedIn](#).

For personal use only

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

| Resolution details | | Instructions given to validly appointed proxies (as at proxy close) | | | | Number of votes cast on the poll (where applicable) | | | Resolution Result |
|--|--------------------|--|--------------------|-----------------------|------------|--|--------------------|------------|--------------------------|
| Resolution | Resolution Type | For | Against | Proxy's Discretion | Abstain | For | Against | Abstain* | Carried / Not Carried |
| 1 Ratification of Placement Shares | Ordinary | 125,751,824 96.99% | 830,879 0.64% | 3,072,494 2.37% | 26,441,848 | 128,824,318 99.36% | 830,879 0.64% | 26,441,848 | Carried |
| 2 Issue of Attaching Options under the Placement | Ordinary | 125,521,809 96.81% | 1,043,994 0.81% | 3,089,394 2.38% | 26,441,848 | 128,611,203 99.19% | 1,043,994 0.81% | 26,441,848 | Carried |
| 3 Issue of Lead Manager Options | Ordinary | 152,875,378 96.48% | 2,499,494 1.58% | 3,072,869 1.94% | 108,420 | 155,948,247 98.42% | 2,499,494 1.58% | 108,420 | Carried |
| 4 Issue of Sub-Underwriter Options | Ordinary | 150,874,436 96.27% | 2,527,914 1.61% | 3,322,494 2.12% | 171,150 | 154,196,930 98.39% | 2,527,914 1.61% | 171,150 | Carried |
| 5 Issue PLC Shares and Opt to Dr Warwick Tong | Ordinary | 151,727,535 97.59% | 672,900 0.43% | 3,072,494 1.98% | 3,083,232 | 154,800,029 99.57% | 672,900 0.43% | 3,083,232 | Carried |
| 6 Issue PLC Shares and Opt to Dr Christopher Burns | Ordinary | 150,907,487 97.54% | 616,900 0.40% | 3,187,998 2.06% | 3,843,776 | 154,095,485 99.60% | 616,900 0.40% | 3,843,776 | Carried |
| 7 Issue PLC Shares and Opt to Dr Robert Peach | Ordinary | 149,687,245 97.14% | 1,337,404 0.87% | 3,072,494 1.99% | 4,459,018 | 152,759,739 99.13% | 1,337,404 0.87% | 4,459,018 | Carried |
| 8 Issue PLC Shares and Opt to Ms Jane Bell | Ordinary | 151,243,614 97.18% | 1,308,984 0.84% | 3,072,494 1.97% | 95,405 | 154,316,108 99.16% | 1,308,984 0.84% | 95,405 | Carried |

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.